Fortress Biotech Inc Pref Series A (FBIOP)vsVertex Pharmaceuticals Inc (VRTX)
FBIOP
Fortress Biotech Inc Pref Series A
$18.45
-1.10%
HEALTHCARE · Cap: $77.81M
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 18285% more annual revenue ($12.59B vs $68.47M). FBIOP leads profitability with a 163.3% profit margin vs 35.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
FBIOP
Hold44
out of 100
Grade: D
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.5%
Fair Value
$13.38
Current Price
$18.45
$5.07 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 79 in profit
Keeps 163 of every $100 in revenue as profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : FBIOP
The primary concerns for FBIOP are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
FBIOP carries more volatility with a beta of 1.21 — expect wider price swings.
FBIOP is growing revenue faster at 14.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (64/100 vs 44/100), backed by strong 35.0% margins and 12.5% revenue growth. FBIOP offers better value entry with a 15.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?